US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.56

+0.79081.30%

Volume:43.28K

Turnover:2.64M

Market Cap:287.49M

PE:20.14

High:61.83

Open:60.98

Low:60.60

Close:60.77

52wk High:64.10

52wk Low:39.36

Shares:4.67M

Float Shares:4.67M

Volume Ratio:2.38

T/O Rate:0.93%

Dividend:1.53

Dividend Rate:2.48%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS

US FDA Approves Roivant-Priovant's Skin Disease Drug

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS

Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/PTH/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.56,"timestamp":1789412935852,"preClose":60.7692,"halted":0,"volume":43281,"delay":0,"changeRate":0.013013171145909514,"floatShares":4670000,"shares":4670000,"eps":3.057033,"marketStatus":"Trading","change":0.7908,"latestTime":"09-14 15:12:49 EDT","open":60.98,"high":61.825,"low":60.6,"amount":2639787.39423,"amplitude":0.020158,"askPrice":61.61,"askSize":189,"bidPrice":61.56,"bidSize":300,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.7692,"sharesOutstanding":2480000,"nav":60.58293,"aum":283728993.67,"dividendRate":0.024777,"bidAskSpread":0.001903,"postHourTrading":{"tag":"盘后","latestPrice":60.85,"preClose":60.7692,"latestTime":"19:30 EDT","volume":14,"amount":850.1752,"timestamp":1789169406061,"change":0.0808,"changeRate":0.00133,"amplitude":0},"volumeRatio":2.379121,"impliedVol":0.1449,"impliedVolPercentile":0.6853},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4670000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.379121,"shares":4670000,"dividePrice":1.5253,"high":61.825,"amplitude":0.020158,"preClose":60.7692,"low":60.6,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.56,"committee":0.226994,"eps":3.057033,"divideRate":0.024777,"volume":43281,"delay":0,"ttmEps":3.057033,"open":60.98,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":61.1284,"twentyDayClose":60.35,"sixtyDayClose":52.7902},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662109816","title":"Lisraya is Commercially Available NOW - Roivant Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662109816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662109816?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:07","pubTimestamp":1787918848,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1RX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060278","title":"Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060278?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:07","pubTimestamp":1787918848,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ROIV","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060570","title":"Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060570","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060570?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:56","pubTimestamp":1787918160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145744656","title":"US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145744656?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:24","pubTimestamp":1787912643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has officially approved Revolution Medicines' self-developed pancreatic cancer treatment, Rasonque, this week. This approval represents a significant triumph for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4588","IE00B2B36J28.USD","LU0109394709.USD","RVMD","LABU","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BBH","LU0320765992.SGD","PTH","BK4585","LU0889565916.HKD","BK4139","IDNA","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037671","title":"Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662037671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:21","pubTimestamp":1787880060,"startTime":"0","endTime":"0","summary":"Earlier this year, an oncology biotech with no drugs on the market-just promising research-was attracting takeover interest. Revolution Medicines stayed independent.This week, that bet paid off.The 12","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","CANC","LU0320765992.SGD","RVMD","IE0009354923.USD","LU0109394709.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IDNA","LU0889565916.HKD","PTH","IE0009355771.USD","BBH","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003883","title":"Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003883","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662003883?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:58","pubTimestamp":1787860715,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) said Thursday the FDA approved LISRAYA for adults with dermatomyositis, with the once-daily pill now available in the US, sending its shares up 1.5%.The approval follows the Ph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LABU","BK4139","PTH","ROIV","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080615","title":"Priovant Therapeutics - Lisraya NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080615?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080613","title":"Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080613?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662806990","title":"US FDA Approves Roivant-Priovant's Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662806990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662806990?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:26","pubTimestamp":1787858771,"startTime":"0","endTime":"0","summary":"US FDA approves Roivant-Priovant's skin disease drugAug 27 (Reuters)-The U.S. Food and Drug Administration said on Thursday it approved a treatment from RoivantROIV.Oand partner Priovant Therapeutics for dermatomyositis, making it the first oral drug for the skin disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O1TO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080316","title":"FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080316","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080316?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:18","pubTimestamp":1787858285,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approves First Oral Drug Indicated To Treat Dermatomyositis In AdultsAug 28 (Reuters)-FDA:FDA: FDA APPROVES FIRST ORAL DRUG INDICATED TO TREAT DERMATOMYOSITIS IN ADULTSFDA: LISRAYA IS THE FIRST FDA-APPROVED ORAL TREATMENT OPTION FOR PATIENTS WITH DERMATOMYOSITIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662803550","title":"FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662803550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662803550?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:14","pubTimestamp":1787858053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008458","title":"Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008458","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008458?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:21","pubTimestamp":1787847665,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","RVMD","CANC","IE0002141913.USD","IE0009355771.USD","PTH","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4139","IDNA","BBH","IE00BJJMRZ35.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704855","title":"Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704855?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:35","pubTimestamp":1787830554,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era** Revolution Medicines'RVMD.Ogroundbreakingpancreatic cancer drug, Rasonque, received the U.S. FDA approval on W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009354923.USD","PTH","IE0009355771.USD","RVMD","CANC","LU0109394709.USD","IDNA","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BBH","IE00BJJMRZ35.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4563","PTH","LU0029874061.USD","IE00B2B36J28.USD","CANC","IE0009354923.USD","LU0889565916.HKD","BK4139","BK4137","RVMD","IE00B4R5TH58.HKD","LU0109394709.USD","BBH","IE00BFTCPJ56.SGD","IMRX","XBI","IDNA","IE0009355771.USD","BK4585","BK4581","XLV","LU0320765992.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LABU","BK4539","HCSG","IE00BJT1NW94.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192894793","title":"Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1192894793","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192894793?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:42","pubTimestamp":1787820126,"startTime":"0","endTime":"0","summary":"Jinbo Bio, a leading player in the recombinant collagen sector, recently published its interim report for the first half of 2026, revealing a notable setback in its growth trajectory. The financial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","RSPH","BK1100","HART","LGHT","AGNG","IEIH","BK1583","GDOC","MEDX","MDEV","LNGR","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662988724","title":"Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230","url":"https://stock-news.laohu8.com/highlight/detail?id=2662988724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662988724?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:38","pubTimestamp":1787798329,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44N0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009354923.USD","PTH","IE0009355771.USD","RVMD","CANC","LU0109394709.USD","IDNA","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BBH","IE00BJJMRZ35.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662574411","title":"Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2662574411","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662574411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:15","pubTimestamp":1787775315,"startTime":"0","endTime":"0","summary":"• BrightSpring reported strong second-quarter revenue and raised its full-year guidance.\n• Wall Street analysts maintained buy ratings with an average price target of $78.97.\n• Annual revenue reached $12.91 billion with a net profit of $190.67 million.","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262133901-market-movers-btsg-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU2324357040.USD","LU2089984988.USD","PTH","LU2468319806.SGD","PSCH","BTSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749358","title":"Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749358","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662749358?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:20","pubTimestamp":1787768430,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.Price: 215.95, Change: +4.57, Percent Change: +2.16","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BBH","IE0009354923.USD","IE00B2B36J28.USD","IE0002141913.USD","BK4139","IE0009355771.USD","CANC","IDNA","LU0320765992.SGD","LU0109394709.USD","RVMD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746776","title":"Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746776","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746776?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:02","pubTimestamp":1787767375,"startTime":"0","endTime":"0","summary":"Price: 215.72, Change: +4.34, Percent Change: +2.05","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","CANC","LU0320765992.SGD","RVMD","IE0009354923.USD","LU0109394709.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IDNA","LU0889565916.HKD","PTH","IE0009355771.USD","BBH","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662462057","title":"Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662462057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662462057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:56","pubTimestamp":1787766961,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4139","IDNA","IE00B4R5TH58.HKD","IE0009354923.USD","LU0889565916.HKD","RVMD","IE0002141913.USD","IE00BJT1NW94.SGD","BBH","PTH","IE00BFTCPJ56.SGD","CANC","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}